Concepedia

Alessandra Vitaliti

AV

Statistics

Publications

22

Citations

1.2K

H-Index

15

Active since

2000

Affiliations

Novartis (Switzerland)(Current)

AstraZeneca (United States)

Roche (Switzerland)

Bristol-Myers Squibb (United States)

Caprion (Canada)

Alessandra Vitaliti is an author at Novartis (Switzerland) specializing in pharmacy, bioanalytical method validation, and medicine.

ORCID

Publications per year

2000–2023

22

Publications

22

The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rate

P Gergely, Barbara Nuesslein‐Hildesheim, Danilo Guerini et al. · British Journal of Pharmacology · 2012 · 304 citations · Full text

, , +15

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

Martin R. Farlow, Niels Andreasen, Marie‐Emmanuelle Riviere et al. · Alzheimer s Research & Therapy · 2015 · 143 citations · Full text

, , +17

Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles

B Astruc, Peter Marbach, Hakim Bouterfa et al. · The Journal of Clinical Pharmacology · 2005 · 122 citations

, , +9

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

Steven P. Piccoli, Devangi Mehta, Alessandra Vitaliti et al. · Bioanalysis · 2019 · 95 citations · Full text

, , +13

Increased expression of H/T-cadherin in tumor-penetrating blood vessels.

Lorenza Wyder, Alessandra Vitaliti, Henriette Schneider et al. · PubMed · 2000 · 81 citations

, , +14

1–5 of 22